- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 26.03. | Gain Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.03. | Gain Therapeutics GAAP EPS of -$0.61 beats by $0.03 | 2 | Seeking Alpha | ||
| 18.03. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Gain Therapeutics reports biomarker data from Parkinson's trial | 1 | Investing.com | ||
| 18.03. | Gain Therapeutics legt vielversprechende Biomarker-Daten aus Parkinson-Studie vor | 18 | Investing.com Deutsch | ||
| 18.03. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 | 2 | GlobeNewswire (USA) | ||
| 03.02. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.01. | Gain Therapeutics reports 81% reduction in Parkinson's biomarker | 13 | Investing.com | ||
| 22.12.25 | Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data | 1 | Investing.com | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 3 | GlobeNewswire (USA) | ||
| 18.12.25 | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease | 536 | GlobeNewswire (Europe) | Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever... ► Artikel lesen | |
| 03.12.25 | Gain Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 01.12.25 | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data | 12 | Investing.com | ||
| 28.11.25 | Gain Therapeutics reicht Prospektnachtrag für Aktienangebot über 35,5 Mio. USD ein | 2 | Investing.com Deutsch | ||
| 28.11.25 | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.11.25 | Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 | 1 | Seeking Alpha | ||
| 18.09.25 | Gain Therapeutics, Inc.: Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease | 279 | GlobeNewswire (Europe) | Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAGE LABS | 14,500 | +0,97 % | BioAge Labs, Inc.: BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP | 120 mg and newly announced 60 mg once-daily doses each achieved =85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 1,330 | +1,53 % | From 75,000 AI tracks hitting Deezer daily to UMG's copyright lawsuit against Quince… it's MBW's weekly round-up | ||
| FRACTYL HEALTH | 0,699 | +9,69 % | Fractyl Health, Inc.: Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,115 | -24,94 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| ERASCA | 10,000 | -6,10 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,720 | -1,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 34,130 | 0,00 % | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,960 | -3,05 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 36,630 | +2,35 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 323,50 | +1,46 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| JANUX THERAPEUTICS | 14,340 | -0,21 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 55,23 | +2,70 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| CG ONCOLOGY | 66,21 | -0,79 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 1,960 | +10,73 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,110 | +1,59 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-0,26 %) liegt der Kurs bei 1,885 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.